Short answer
Voyager Therapeutics, Inc. (VYGR) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M (down 70.0% year over year) with net income of −$25M.
Q3 2026 key financials · XBRL
- Revenue
- $4M
- −70.0% YoY · +26.8% QoQ
- Net income
- −$25M
- +11.5% YoY · −0.9% QoQ
- Operating margin
- -658.2%
- EPS (diluted)
- −$0.40
- +14.9% YoY · +0.0% QoQ
Source: XBRL data from the Voyager Therapeutics, Inc. (VYGR) Q3 2026 10-Q on SEC EDGAR. USD.
Voyager Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $4.0M, down from $13.4M YoY, a $9.4M decrease
- Net loss $24.7M vs $27.9M YoY, operating expenses $30.4M vs $44.0M
- Best line: Novartis collaboration revenue $3.1M, worst: Neurocrine revenue $0.5M vs $11.1M YoY
- Operating cash use $78.9M through September, cash, equivalents and securities $132.1M
- Runway into Q2 2028, VY1706 dosing expected in coming months, acute safety data anticipated Q1 2027
Risk Factors
- No material risk-factor changes identified; filing references carried-forward 10-K risks
- Clinical development risk: VY1706 trial expected to enroll up to 18 patients across three cohorts
- Regulatory risk: FDA-cleared VY1706 IND, but clinical dosing remains subject to enrollment timing
- Collaboration concentration risk: nine-month collaboration revenue fell to $9.8 million from $25.0 million
- Liquidity risk: cash, cash equivalents and marketable securities totaled $132.1 million, expected to fund operations into second quarter 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Voyager Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.